These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 10213372

  • 1. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
    Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR.
    Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
    [Abstract] [Full Text] [Related]

  • 2. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
    Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P.
    Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
    [Abstract] [Full Text] [Related]

  • 3. Grapefruit juice activates P-glycoprotein-mediated drug transport.
    Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ.
    Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
    [Abstract] [Full Text] [Related]

  • 4. Mdr1 limits CYP3A metabolism in vivo.
    Lan LB, Dalton JT, Schuetz EG.
    Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
    [Abstract] [Full Text] [Related]

  • 5. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
    Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ.
    Cancer Res; 1999 Aug 15; 59(16):3944-8. PubMed ID: 10463589
    [Abstract] [Full Text] [Related]

  • 6. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
    Wandel C, Kim RB, Guengerich FP, Wood AJ.
    Drug Metab Dispos; 2000 Aug 15; 28(8):895-8. PubMed ID: 10901697
    [Abstract] [Full Text] [Related]

  • 7. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein.
    Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R.
    Drug Metab Dispos; 2003 Jul 15; 31(7):861-9. PubMed ID: 12814962
    [Abstract] [Full Text] [Related]

  • 8. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.
    Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T.
    Eur J Pharmacol; 1998 Oct 09; 358(3):289-94. PubMed ID: 9822896
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The xenobiotic inhibitor profile of cytochrome P4502C8.
    Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO.
    Br J Clin Pharmacol; 2000 Dec 09; 50(6):573-80. PubMed ID: 11136296
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
    Zhang Y, Guo X, Lin ET, Benet LZ.
    Drug Metab Dispos; 1998 Apr 09; 26(4):360-6. PubMed ID: 9531525
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
    Katoh M, Nakajima M, Yamazaki H, Yokoi T.
    Pharm Res; 2000 Oct 09; 17(10):1189-97. PubMed ID: 11145223
    [Abstract] [Full Text] [Related]

  • 17. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
    Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW.
    Chem Res Toxicol; 2001 Dec 09; 14(12):1596-603. PubMed ID: 11743742
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, Takano M.
    Drug Metab Dispos; 2001 Feb 09; 29(2):145-51. PubMed ID: 11159804
    [Abstract] [Full Text] [Related]

  • 19. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
    Yu DK.
    J Clin Pharmacol; 1999 Dec 09; 39(12):1203-11. PubMed ID: 10586385
    [Abstract] [Full Text] [Related]

  • 20. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
    Zhang Y, Benet LZ.
    Clin Pharmacokinet; 2001 Dec 09; 40(3):159-68. PubMed ID: 11327196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.